EUCTR2004-000119-24-IT进行中（未招募）不适用
A randomized,two-cohort fase II study of two doses of BMS-275183 given on a weekle schedule in patients with pre-treated non-small cell lung cancer
BRISTOL-M.SQUIBB0 个研究点开始时间: 2005年7月29日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
IMCY-0098 Proof of ACtion in Type 1 Diabetes - IMPACT StudyType 1 DiabetesEUCTR2020-001317-20-LTImcyse SA84
进行中（未招募）
1 期
IMCY-0098 Proof of ACtion in Type 1 Diabetes - IMPACT StudyMedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 1 DiabetesEUCTR2020-001317-20-BEImcyse SA84
进行中（未招募）
1 期
IMCY-0098 Proof of ACtion in Type 1 Diabetes - IMPACT StudyMedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 1 DiabetesEUCTR2020-001317-20-SIImcyse SA84
进行中（未招募）
1 期
A research study of a new investigational medicinal product for the treatment of Duchenne Muscular Dystrophy patientsMedDRA version: 20.1Level: PTClassification code 10052655Term: Duchenne muscular dystrophy gene carrierSystem Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne Muscular DystrophyEUCTR2019-000601-77-NLSarepta Therapeutics, Inc.57
进行中（未招募）
1 期
A research study of a new investigational medicinal product for the treatment of Duchenne Muscular Dystrophy patientsDuchenne Muscular DystrophyMedDRA version: 20.1Level: PTClassification code 10052655Term: Duchenne muscular dystrophy gene carrierSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-000601-77-GBSarepta Therapeutics, Inc.70